Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Medtronic
McKesson
Harvard Business School
Baxter

Last Updated: May 28, 2022

Investigational Drug Information for Ademetionine


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Ademetionine?

Ademetionine is an investigational drug.

There have been 7 clinical trials for Ademetionine. The most recent clinical trial was a Phase 3 trial, which was initiated on September 30th 2020.

The most common disease conditions in clinical trials are Chemical and Drug Induced Liver Injury, Chemical and Drug Induced Liver Injury, Chronic, and Hepatitis B. The leading clinical trial sponsors are Beijing 302 Hospital, MSI Methylation Sciences, Inc., and Zhejiang Hisun Pharmaceutical Co. Ltd.

There are six hundred and eighty-seven US patents protecting this investigational drug and ten international patents.

Recent Clinical Trials for Ademetionine
TitleSponsorPhase
Glucocorticosteroid Therapy on Drug-induced Liver Injury: a Prospective Non-randomized Concurrent Control TrialLi YangPhase 4
36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILIBeijing 302 HospitalPhase 1/Phase 2
Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILIBeijing 302 HospitalPhase 1/Phase 2

See all Ademetionine clinical trials

Clinical Trial Summary for Ademetionine

Top disease conditions for Ademetionine
Top clinical trial sponsors for Ademetionine

See all Ademetionine clinical trials

US Patents for Ademetionine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ademetionine See Plans and Pricing Method and culture medium for improving pluripotent stem cell differentiation inducing efficiency NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Kumamoto, JP) See Plans and Pricing
Ademetionine See Plans and Pricing Devices and methods for continuous analyte monitoring DexCom, Inc. (San Diego, CA) See Plans and Pricing
Ademetionine See Plans and Pricing Advanced analyte sensor calibration and error detection DexCom, Inc. (San Diego, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ademetionine

Drugname Country Document Number Estimated Expiration Related US Patent
Ademetionine European Patent Office EP2644694 2030-10-28 See Plans and Pricing
Ademetionine Japan JP5938726 2030-10-28 See Plans and Pricing
Ademetionine Japan JPWO2012056997 2030-10-28 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Medtronic
McKesson
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.